CN107406423B - 强效γ-分泌酶调节剂 - Google Patents

强效γ-分泌酶调节剂 Download PDF

Info

Publication number
CN107406423B
CN107406423B CN201580071837.8A CN201580071837A CN107406423B CN 107406423 B CN107406423 B CN 107406423B CN 201580071837 A CN201580071837 A CN 201580071837A CN 107406423 B CN107406423 B CN 107406423B
Authority
CN
China
Prior art keywords
substituted
unsubstituted
group
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580071837.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107406423A (zh
Inventor
S·L·瓦格纳
W·C·莫布里
R·E·坦齐
G·约翰逊
R·巴克尔
N·梅休
R·J·赫尔
K·D·赖尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
University of California San Diego UCSD
Original Assignee
General Hospital Corp
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, University of California San Diego UCSD filed Critical General Hospital Corp
Publication of CN107406423A publication Critical patent/CN107406423A/zh
Application granted granted Critical
Publication of CN107406423B publication Critical patent/CN107406423B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580071837.8A 2014-10-31 2015-10-30 强效γ-分泌酶调节剂 Active CN107406423B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073553P 2014-10-31 2014-10-31
US62/073,553 2014-10-31
PCT/US2015/058429 WO2016070107A1 (en) 2014-10-31 2015-10-30 Potent gamma-secretase modulators

Publications (2)

Publication Number Publication Date
CN107406423A CN107406423A (zh) 2017-11-28
CN107406423B true CN107406423B (zh) 2020-06-16

Family

ID=55858421

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580071837.8A Active CN107406423B (zh) 2014-10-31 2015-10-30 强效γ-分泌酶调节剂

Country Status (8)

Country Link
US (2) US10472346B2 (https=)
EP (1) EP3212633B1 (https=)
JP (1) JP6672296B2 (https=)
CN (1) CN107406423B (https=)
AU (1) AU2015338946B2 (https=)
CA (1) CA2966423C (https=)
MX (1) MX381224B (https=)
WO (1) WO2016070107A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10472346B2 (en) 2014-10-31 2019-11-12 The General Hospital Corporation Potent gamma-secretase modulators
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
EP3728228A1 (en) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
JP7649257B2 (ja) * 2019-05-13 2025-03-19 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
WO2021174176A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
US20240368163A1 (en) * 2021-08-30 2024-11-07 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
WO1999021537A1 (fr) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. Feuille de timbre cutane et procede de production d'une feuille de base pour timbre
AU2003259965A1 (en) 2002-08-20 2004-03-11 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
HRP20090264T1 (hr) 2004-12-09 2009-06-30 F. Hoffmann - La Roche Ag Derivati fenil-piperazin metanona
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
ES2336625T3 (es) 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
WO2008088881A1 (en) 2007-01-19 2008-07-24 Xcovery, Inc. Kinase inhibitor compounds
US8410142B2 (en) 2007-03-02 2013-04-02 Merck Sharp & Dohme Corp. Bipyridine carboxamide orexin receptor antagonists
GB0720444D0 (en) * 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2009119088A1 (ja) 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
WO2010098487A1 (en) 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012180281A (ja) 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
JP2012532912A (ja) 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
JP2013028538A (ja) 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
JP2013523658A (ja) 2010-03-26 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのピラゾリル‐ピリミジン
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
US10472346B2 (en) 2014-10-31 2019-11-12 The General Hospital Corporation Potent gamma-secretase modulators

Also Published As

Publication number Publication date
MX2017005715A (es) 2018-02-23
EP3212633A1 (en) 2017-09-06
CA2966423A1 (en) 2016-05-06
EP3212633B1 (en) 2019-12-04
JP6672296B2 (ja) 2020-03-25
US10472346B2 (en) 2019-11-12
US20180093967A1 (en) 2018-04-05
BR112017009010A2 (pt) 2017-12-26
MX381224B (es) 2025-03-12
WO2016070107A1 (en) 2016-05-06
JP2017533237A (ja) 2017-11-09
CA2966423C (en) 2023-10-24
AU2015338946A1 (en) 2017-06-15
EP3212633A4 (en) 2018-07-25
US20200055840A1 (en) 2020-02-20
AU2015338946B2 (en) 2020-06-11
US11117884B2 (en) 2021-09-14
CN107406423A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
CN107406423B (zh) 强效γ-分泌酶调节剂
CN111315737B (zh) 经砜吡啶烷基酰胺取代的杂芳基化合物
CN113227071A (zh) 治疗与IL-12、IL-23和/或IFN-α的调节相关的病症的酰胺取代的杂环化合物
CN103764635B (zh) 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
CN105764514B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
TWI635083B (zh) １，４－雙取代嗒類似物及運動神經元存活（ｓｍｎ）缺乏相關病況之治療方式
CN111566103B (zh) 作为激酶抑制剂的氨基咪唑并吡嗪
JP7637626B2 (ja) アミド二置換のピリジンまたはピリダジン化合物
US10023534B2 (en) Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
IL287521B1 (en) History of 3-amino-h4-benzo[e][4,2,1]thiadiazine 1,1-dioxide as MRGX2 inhibitors
TW200403210A (en) Benzamide derivatives
CN104936955A (zh) 噻二唑类似物以及治疗与smn缺乏相关的病症的方法
CN107635992B (zh) 用作tnf抑制剂的三环杂环化合物
TW202028210A (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
TW201326155A (zh) 作為ｇｐｒ１１９調節劑之經哌啶基取代的內醯胺
TWI400238B (zh) ２－酮基烷基－１－哌－２－酮衍生物、其製備及其治療用途
CN102124006B (zh) (桥接的哌嗪基)-1-烷酮衍生物及其作为p75抑制剂的用途
WO2025153625A1 (en) Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
CN111372579A (zh) 取代的苯基磺酰基苯基三唑硫酮和其用途
JP7025542B2 (ja) Ｔｇｆ－ベータ阻害剤としてのオキサジアゾール及びチアジアゾール
BR122023017838B1 (pt) Uso de moduladores potentes de gama-secretase e método in vitro para reduzir o nível de uma aloforma de peptídeo ab em uma célula
BR112017009010B1 (pt) MODULADORES POTENTES DE GAMA-SECRETASE, SEUS USOS, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA REDUZIR O NÍVEL DE UMA ALOFORMA DE PEPTÍDEO Aß EM UMA CÉLULA E PRÓ-FÁRMACO
CN118852111A (zh) 一种哌啶基吲哚化合物的晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant